Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy .
Helsinn Healthcare S.A.February 18, 2021 GMT
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”).
Mechlorethamine gel 0.016%, also known as chlormethine gel, is approved for use in multiple countries including the US and EU and is marketed under the trade names VALCHLOR® and LEDAGA®. The authorized use for each country varies based on the design of the registrational trial and the individual hea
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
SurgePays Welcomes David May, Leader in the Financial Industry with Deep Ties to Convenience .
Surge Holdings, Inc.February 18, 2021 GMT
BARTLETT, Tenn., Feb. 18, 2021 (GLOBE NEWSWIRE) SurgePays, Inc. (OTCQB: SURG) (“SurgePays” or the “Company”), a fintech company building a next generation supply chain network that can offer wholesale goods and financial services for the underbanked more cost efficiently than traditional distribution models, announces today that David May, a financial professional with significant experience in providing solutions to convenience stores, has joined the Company’s Board of Directors.
Press release content from Business Wire. The AP news staff was not involved in its creation.
IDACORP, Inc. Announces Fourth Quarter and Year-End 2020 Results, Initiates 2021 Earnings Guidance
February 18, 2021 GMT
BOISE, Idaho (BUSINESS WIRE) Feb 18, 2021
IDACORP, Inc. (NYSE: IDA) reported fourth quarter 2020 net income attributable to IDACORP of $37.5 million, or $0.74 per diluted share, compared with $47.1 million, or $0.93 per diluted share, in the fourth quarter of 2019. IDACORP reported 2020 net income attributable to IDACORP of $237.4 million, or $4.69 per diluted share, compared with $232.9 million, or $4.61 per diluted share, in 2019.
“I am proud to announce IDACORP has achieved its 13th straight year of growth in earnings per share,” said IDACORP President and Chief Executive Officer Lisa Grow. “Continued robust customer growth of 2.7% over the previous year for Idaho Power was a significant driver of this accomplishment. This growth, combined with lower operati
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
EnviroKlenz Opens New Air Purifier Production Facility in Topeka, Kansas, Bringing Jobs and .
EnviroKlenzFebruary 18, 2021 GMT
TOPEKA, Kan., Feb. 18, 2021 (GLOBE NEWSWIRE) EnviroKlenz, a leading indoor air quality and technology company that developed a patented earth mineral technology originally designed and still used today by the U.S. military to destroy chemical warfare agents and toxic industrial chemicals, announces its new production facility in Topeka, Kansas. At the new facility, research scientists will discover new technology and increase production of air purifiers, furthering awareness of indoor air quality in the Midwest. All EnviroKlenz air purifiers are made in the U.S.A., supporting the country’s economy and stimulating the local economy.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch
February 19, 2021 GMT
HAYWARD, Calif. (BUSINESS WIRE) Feb 19, 2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX ® procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company’s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company’s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business.